Pelin Kilickaya
Pelin Kilickaya has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Yalcin Hacioglu
Univ Hlth Sci Turkey, Istanbul Training & Res Hosp, Clin Family Med, Istanbul, Turkey
3 shared publications - Esra Hatipoglu
Department of Endocrinology and Metabolism, Basaksehir Cam and Sakura City Hospital University of Health Sciences Istanbul Turkey
2 shared publications - Mehmet Emin Pişkinpaşa
Univ Hlth Sci Turkey, Istanbul Training & Res Hosp, Clin Internal Med, Istanbul, Turkey
2 shared publications - Mutlu Niyazoglu
Division of Endocrinology, Department of Internal Medicine, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
2 shared publications - Turgut Karabag
Department of Cardiology, Istanbul Training and Research Hospital, University of Health Sciences, 34098 Istanbul, Türkiye
2 shared publications - Burcu Hacıoğlu
Department of Internal Medicine, Haseki Education and Research Hospital, University of Health Sciences, Istanbul, Turkey
1 shared publication
Latest Publications
- 1 August 2022
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 23 (3) , 179-182
Increased Serum Growth Differentiation Factor 15 Levels may be Associated with Diastolic Dysfunction in Acromegaly
- 1 August 2022
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 23 (3) , 179-182
Increased Serum Growth Differentiation Factor 15 Levels may be Associated with Diastolic Dysfunction in Acromegaly
- 1 February 2022
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 23 (1) , 74-78
Correlation of Coronary Calcium Scores with Growth Differentiation Factor-15 Levels in Patients with Coronary Artery Disease
- 1 February 2022
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 23 (1) , 74-78
Correlation of Coronary Calcium Scores with Growth Differentiation Factor-15 Levels in Patients with Coronary Artery Disease
- 11 October 2020
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (12) , 2051-2054
Acromegaly might not negatively affect microvascular circulation
Background: Endothelial dysfunction and atherosclerosis are well known complications of acromegaly. However, current data on microvascular circulation are limited.Aims: To evaluate microvascular circulation in patients with acromegaly.Methods: This comparative study included a total of 21 patients with acromegaly and 20 age‐ and sex‐matched healthy subjects. A stereomicroscope under ×100 magnification was used by a single rheumatologist to evaluate the capillary dimensions (capillary loop length, capillary width) and capillary/mm count in the capillaries of subjects. Statistical data analysis was conducted using the SPSS 15.0 package program.Results: The mean number of capillaries per millilitre (normal ≥8/mL) in the acromegaly group (AG) and healthy controls (HC) was 7.67 ± 1.88 and 8.67 ± 0.65, respectively (P = 0.04). In the AG and the HC, the number of tortuous capillaries, the mean capillary loop length and the mean capillary width were not different. Although the median number of capillaries in the AG was lower than in the HC, it was still within normal limits.Conclusion: Although the number of capillaries was statistically lower in patients with acromegaly, they were within a normal range and the difference was not clinically significant. Moreover, there was no difference in morphological characteristics between the groups. While endothelial dysfunction is the earliest known marker of the atherosclerotic process and is considered to be one of the complications of acromegaly, the disease may not result in impairment of microvasculature of those people afflicted by it.
- 11 October 2020
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (12) , 2051-2054
Acromegaly might not negatively affect microvascular circulation
Background: Endothelial dysfunction and atherosclerosis are well known complications of acromegaly. However, current data on microvascular circulation are limited.Aims: To evaluate microvascular circulation in patients with acromegaly.Methods: This comparative study included a total of 21 patients with acromegaly and 20 age‐ and sex‐matched healthy subjects. A stereomicroscope under ×100 magnification was used by a single rheumatologist to evaluate the capillary dimensions (capillary loop length, capillary width) and capillary/mm count in the capillaries of subjects. Statistical data analysis was conducted using the SPSS 15.0 package program.Results: The mean number of capillaries per millilitre (normal ≥8/mL) in the acromegaly group (AG) and healthy controls (HC) was 7.67 ± 1.88 and 8.67 ± 0.65, respectively (P = 0.04). In the AG and the HC, the number of tortuous capillaries, the mean capillary loop length and the mean capillary width were not different. Although the median number of capillaries in the AG was lower than in the HC, it was still within normal limits.Conclusion: Although the number of capillaries was statistically lower in patients with acromegaly, they were within a normal range and the difference was not clinically significant. Moreover, there was no difference in morphological characteristics between the groups. While endothelial dysfunction is the earliest known marker of the atherosclerotic process and is considered to be one of the complications of acromegaly, the disease may not result in impairment of microvasculature of those people afflicted by it.
- 30 November 2014
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 23 (6) , 1759-1767
A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study
There is clinical need to predict risk of febrile neutropenia before a specific cycle of chemotherapy in cancer patients. Data on 3882 chemotherapy cycles in 1089 consecutive patients with lung, breast, and colon cancer from four teaching hospitals were used to construct a predictive model for febrile neutropenia. A final nomogram derived from the multivariate predictive model was prospectively confirmed in a second cohort of 960 consecutive cases and 1444 cycles. The following factors were used to construct the nomogram: previous history of febrile neutropenia, pre-cycle lymphocyte count, type of cancer, cycle of current chemotherapy, and patient age. The predictive model had a concordance index of 0.95 (95 % confidence interval (CI) = 0.91–0.99) in the derivation cohort and 0.85 (95 % CI = 0.80–0.91) in the external validation cohort. A threshold of 15 % for the risk of febrile neutropenia in the derivation cohort was associated with a sensitivity of 0.76 and specificity of 0.98. These figures were 1.00 and 0.49 in the validation cohort if a risk threshold of 50 % was chosen. This nomogram is helpful in the prediction of febrile neutropenia after chemotherapy in patients with lung, breast, and colon cancer. Usage of this nomogram may help decrease the morbidity and mortality associated with febrile neutropenia and deserves further validation.
- 30 November 2014
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 23 (6) , 1759-1767
A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study
There is clinical need to predict risk of febrile neutropenia before a specific cycle of chemotherapy in cancer patients. Data on 3882 chemotherapy cycles in 1089 consecutive patients with lung, breast, and colon cancer from four teaching hospitals were used to construct a predictive model for febrile neutropenia. A final nomogram derived from the multivariate predictive model was prospectively confirmed in a second cohort of 960 consecutive cases and 1444 cycles. The following factors were used to construct the nomogram: previous history of febrile neutropenia, pre-cycle lymphocyte count, type of cancer, cycle of current chemotherapy, and patient age. The predictive model had a concordance index of 0.95 (95 % confidence interval (CI) = 0.91–0.99) in the derivation cohort and 0.85 (95 % CI = 0.80–0.91) in the external validation cohort. A threshold of 15 % for the risk of febrile neutropenia in the derivation cohort was associated with a sensitivity of 0.76 and specificity of 0.98. These figures were 1.00 and 0.49 in the validation cohort if a risk threshold of 50 % was chosen. This nomogram is helpful in the prediction of febrile neutropenia after chemotherapy in patients with lung, breast, and colon cancer. Usage of this nomogram may help decrease the morbidity and mortality associated with febrile neutropenia and deserves further validation.